ASIT+TM products characteristics have been confirmed in two independent phase II clinical trials in about 200 patients with grass pollen rhinitis:

profile

  • low incidence of side effects

  • short course treatment over 3 weeks

  • induction of antibodies blocking allergic reactions

  • reduction of the reactivity to an allergen provocation test